CEBPZ and acute myeloid leukemia: Moreover, survival in non-GO patients was comparatively low relative to other contemporary studies of IC-eligible CBF-AML patients [16–18, 20], possibly reflecting heterogeneity or suboptimal chemotherapy backbones in some of the included trials.